HALB (Halberd) Cash Flow from Financing: $0.24 Mil (TTM As of Jul. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Halberd Cash Flow from Financing?

Halberd HALB Cash Flow from Financing is $0.24 Mil as of Jul. 2023.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jul. 2023, Halberd received $0.24 Mil more from issuing new shares than it paid to buy back shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Halberd earned $0.24 Mil on financial activities for the six months ended in Jul. 2023.


Halberd  (OTCPK:HALB) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Halberd's issuance of stock for the six months ended in Jul. 2023 was $0.24 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Halberd's repurchase of stock for the six months ended in Jul. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Halberd's net issuance of debt for the six months ended in Jul. 2023 was $0.00 Mil. Halberd received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Halberd's net issuance of preferred for the six months ended in Jul. 2023 was $0.00 Mil. Halberd paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Halberd's cash flow for dividends for the six months ended in Jul. 2023 was $0.00 Mil. Halberd received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Halberd's other financing for the six months ended in Jul. 2023 was $0.00 Mil. Halberd received $0.00 Mil on other financial activities.


Halberd Cash Flow from Financing Related Terms


Halberd Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for Halberd's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd Cash Flow from Financing Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Cash Flow from Financing
0.31 0.89 0.24

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Cash Flow from Financing 0.31 0.89 0.24

Halberd Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Halberd's Cash from Financing for the fiscal year that ended in Jul. 2023 is calculated as:

Halberd's Cash from Financing for the quarter that ended in Jul. 2023 is:


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in Jul. 2023 was $0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Financing of $0.24 Mil mean?
Halberd (HALB) has a Cash Flow from Financing of $0.24 Mil as of Jul. 2023. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Halberd and its competitors.
Is Halberd's Cash Flow from Financing too high?
Halberd's current Cash Flow from Financing is $0.24 Mil.
How does Halberd's Cash Flow from Financing compare to GRI and OCEA?
Halberd's Cash Flow from Financing of $0.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Halberd and its competitors. Halberd's current Cash Flow from Financing is $0.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halberd stock overvalued right now?
Halberd (HALB) has a current Cash Flow from Financing of $0.24 Mil. The current Cash Flow from Financing is $0.24 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Halberd (HALB), the current Cash Flow from Financing is $0.24 Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Halberd Business Description

Address P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.